<PAGE>
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20569
FORM 10-Q
[X ] Quarterly Report Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Or
[ ] Transition Report Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
<TABLE>
<S> <C>
For the Quarterly Period Ended March 31, 2000 Commission file number 0-23150
-------------- -------
</TABLE>
IBIS TECHNOLOGY CORPORATION
- --------------------------------------------------------------------------------
(Exact name of registrant as specified in its charter)
Massachusetts 04-2987600
- ------------------------------- -------------------
(State or other jurisdiction of (I.R.S. Employer
incorporation or organization) Identification No.)
32 Cherry Hill Drive, Danvers, MA 01923
- --------------------------------------------------------------------------------
(Address of principal executive offices) (Zip Code)
(978) 777-4247
- --------------------------------------------------------------------------------
(Registrant's telephone number, including area code)
Indicate by check mark whether the registrant (1) has filed all reports required
to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during
the preceding 12 months (or for such shorter period that the registrant was
required to file such reports), and (2) has been subject to such filing
requirements for the past 90 days.
Yes X No ___
8,295,576 shares of Common Stock, par value $.008, were
outstanding on May 9, 2000.
Total Number of Pages 19
Exhibit Index at Page 18
1
<PAGE>
IBIS TECHNOLOGY CORPORATION
INDEX
<TABLE>
<CAPTION>
PART 1 - FINANCIAL INFORMATION PAGE
- ------------------------------- NUMBER
------
<S> <C>
Item 1 - Financial Statements:
Balance Sheets
December 31, 1999 and March 31, 2000 ....................... 3
Statements of Operations
Three Months Ended March 31, 1999 and 2000 ................. 4
Statements of Cash Flows
Three Months Ended March 31, 1999 and 2000 .................. 5
Notes to Financial Statements .................................. 6
Item 2 - Management's Discussion and Analysis of Financial
Condition and Results of Operations ........................ 10
Item 3 - Quantitative and Qualitative Disclosure About Market Risk 15
PART II - OTHER INFORMATION
Item 1 - Legal Proceedings ......................................... 16
Item 2 - Changes in Securities ..................................... 16
Item 3 - Defaults upon Senior Securities ........................... 16
Item 4 - Submission of Matters to a Vote of Security Holders ....... 16
Item 5 - Other Information ......................................... 16
Item 6 - Exhibits and Reports on Form 8-K .......................... 16
Signatures ......................................................... 17
Exhibit Index ...................................................... 18
</TABLE>
2
<PAGE>
IBIS TECHNOLOGY CORPORATION
BALANCE SHEETS
<TABLE>
<CAPTION>
(UNAUDITED)
DECEMBER 31, MARCH 31,
1999 2000
------------ ------------
<S> <C> <C>
ASSETS
CURRENT ASSETS:
Cash and cash equivalents ................................................................... $ 36,361,621 $ 32,072,987
Accounts receivable, trade, net ............................................................. 3,585,824 3,527,996
Unbilled revenue ............................................................................ 1,469,215 1,656,453
Inventories (note 3) ........................................................................ 6,876,002 7,851,226
Prepaid expenses and other current assets ................................................... 333,742 196,198
------------ ------------
Total current assets .................................................................. 48,626,404 45,304,860
------------ ------------
Property and equipment ......................................................................... 14,346,200 17,253,442
Less: Accumulated depreciation and amortization ............................................. (9,370,156) (9,658,546)
------------ ------------
Net property and equipment ............................................................ 4,976,044 7,594,896
Patents and other assets, net .................................................................. 125,056 377,511
------------ ------------
Total assets .......................................................................... $ 53,727,504 $ 53,277,267
============ ============
LIABILITIES AND STOCKHOLDERS' EQUITY
CURRENT LIABILITIES:
Capital lease obligation, current........................................................... $ 9,557 $ 9,819
Accounts payable ............................................................................ 1,624,451 1,699,048
Accrued liabilities ......................................................................... 2,148,755 1,474,551
Deferred revenue ............................................................................ 1,534,369 1,527,702
------------ ------------
Total current liabilities ............................................................. 5,317,132 4,711,120
Capital lease obligation, noncurrent ........................................................... 30,073 27,517
------------ ------------
Total liabilities ..................................................................... 5,347,205 4,738,637
------------ ------------
STOCKHOLDERS' EQUITY:
Undesignated preferred stock, $.01 par value ................................................
Authorized 2,000,000 shares; none issued ................................................... -- --
Common stock, $.008 par value ...............................................................
Authorized 20,000,000 shares; issued 8,172,800 shares and
8,270,708 shares in 1999 and 2000, respectively ............................................ 65,382 66,166
Additional paid-in capital ................................................................. 63,543,777 64,072,623
Accumulated deficit ........................................................................ (15,228,860) (15,600,159)
------------ ------------
Total stockholders' equity ............................................................ 48,380,299 48,538,630
------------ ------------
Total liabilities and stockholders' equity ............................................ $ 53,727,504 $ 53,277,267
============ ============
</TABLE>
See accompanying notes to financial statements.
3
<PAGE>
IBIS TECHNOLOGY CORPORATION
STATEMENTS OF OPERATIONS
(UNAUDITED)
<TABLE>
<CAPTION>
THREE MONTHS ENDED
MARCH 31,
1999 2000
----------- -----------
<S> <C> <C>
SALES AND REVENUE:
Product sales ..................................... $ 1,299,485 $ 1,643,760
Contract and other revenue ........................ 285,626 79,408
Equipment revenue ................................. 2,862,752 315,944
----------- -----------
Total sales and revenue (notes 2 and 5) ....... 4,447,863 2,039,112
COST OF SALES AND REVENUE:
Cost of product sales ............................. 1,246,084 933,020
Cost of contract and other revenue ................ 104,665 52,244
Cost of equipment revenue ......................... 1,970,966 132,254
----------- -----------
Total cost of sales and revenue ............... 3,321,714 1,117,518
----------- -----------
Gross profit .................................. 1,126,149 921,594
----------- -----------
OPERATING EXPENSES:
General and administrative ........................ 434,448 446,744
Marketing and selling ............................. 207,170 427,020
Research and development .......................... 386,370 913,085
----------- -----------
Total operating expenses ...................... 1,027,988 1,786,849
----------- -----------
Income (loss) from operations ................. 98,161 (865,255)
----------- -----------
OTHER INCOME (EXPENSE):
Interest income ................................... 156,495 501,660
Interest expense .................................. (18,152) (7,328)
Other ............................................. 10,833 880
----------- -----------
Total other income ............................ 149,176 495,212
----------- -----------
Income (loss) before income taxes ............. 247,337 (370,043)
Income tax expense .................................. 1,256 1,256
----------- -----------
Net income (loss) ............................. $ 246,081 $ (371,299)
=========== ===========
Net income (loss) per common share:
Basic .............................................. $ 0.04 $ (0.05)
=========== ===========
Diluted ............................................ $ 0.03 $ (0.05)
=========== ===========
Weighted average number of common shares
Outstanding:
Basic .............................................. 6,878,188 8,210,655
=========== ===========
Diluted ............................................ 7,198,864 8,210,655
=========== ===========
</TABLE>
See accompanying notes to financial statements.
4
<PAGE>
IBIS TECHNOLOGY CORPORATION
STATEMENT OF CASH FLOWS
(UNAUDITED)
<TABLE>
<CAPTION>
THREE MONTHS ENDED
MARCH 31,
----------------------------
1999 2000
------------ ------------
<S> <C> <C>
CASH FLOWS FROM OPERATING ACTIVITIES:
Net income (loss) ................................................ $ 246,081 $ (371,299)
Adjustments to reconcile net income (loss) to net cash provided by
(used in) operating activities:
Depreciation and amortization .................................. 334,018 307,462
Gain on sale of equipment ...................................... -- 880
Changes in operating assets and liabilities:
Accounts receivable, trade ................................. (3,085,439) 57,828
Unbilled revenue ........................................... 128,840 (187,238)
Inventories ................................................ 963,934 (975,224)
Prepaid expenses and other current assets .................. (23,715) 137,544
Accounts payable ........................................... 1,172,112 74,597
Accrued liabilities and deferred revenue ................... 728,539 (680,871)
------------ ------------
Net cash provided by (used in) operating activities ........ 464,370 (1,636,321)
------------ ------------
CASH FLOWS FROM INVESTING ACTIVITIES:
Additions to property and equipment, net ......................... (269,774) (2,923,264)
Other assets ..................................................... (7,425) (256,385)
------------ ------------
Net cash used in investing activities ...................... (277,199) (3,179,649)
------------ ------------
CASH FLOWS FROM FINANCING ACTIVITIES:
Payments of capital lease obligations ............................ (131,658) (2,294)
Exercise of stock options ........................................ 295,895 529,630
------------ ------------
Net cash provided by financing activities .................. 164,237 527,336
------------ ------------
Net increase (decrease) in cash and cash equivalents ....... 351,408 (4,288,634)
Cash and cash equivalents, beginning of period ...................... 12,819,366 36,361,621
------------ ------------
Cash and cash equivalents, end of period ............................ $ 13,170,774 $ 32,072,987
============ ============
SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION:
Cash paid during the period for interest ......................... $ 18,152 $ 7,328
============ ============
</TABLE>
See accompanying notes to financial statements.
5
<PAGE>
IBIS TECHNOLOGY CORPORATION
NOTES TO FINANCIAL STATEMENTS
(UNAUDITED)
(1) INTERIM FINANCIAL STATEMENTS
The accompanying financial statements are unaudited, except for the
Balance Sheet as of December 31, 1999, and have been prepared by Ibis in
accordance with generally accepted accounting principles.
In the opinion of management, the interim financial statements include
all adjustments which consist only of normal and recurring adjustments necessary
for a fair presentation of Ibis' financial position and results of operations.
Results of operations for the interim periods are not necessarily indicative of
the results to be expected for the full year. These financial statements should
be read in conjunction with the financial statements of Ibis as of and for the
year ended December 31, 1999 which are included in the Annual Report on Form
10-K.
(2) REVENUE RECOGNITION
Product and spare part sales are recognized upon shipment. Revenue
derived from consulting and support services are recognized upon performance.
Contract and equipment revenue are recognized on the percentage-of-completion
method. Provisions for anticipated losses are made in the period in which such
losses become determinable. Unbilled revenue represents equipment and contract
revenue earned but not yet billable based on the terms of the contract which
include shipment of the product, achievement of milestones or completion of the
contract.
(3) INVENTORIES
Inventories consist of the following:
<TABLE>
<CAPTION>
DECEMBER 31, MARCH 31,
1999 2000
---------- ----------
<S> <C> <C>
Raw materials ............ $ 129,786 $ 174,250
Work in process .......... 46,639 348,347
Finished goods ........... 28,685 58,734
---------- ----------
Subtotal wafer inventory 205,110 581,331
Equipment inventory ...... 6,670,892 7,269,895
---------- ----------
Total inventories .. $6,876,002 $7,851,226
========== ==========
</TABLE>
6
<PAGE>
IBIS TECHNOLOGY CORPORATION
NOTES TO FINANCIAL STATEMENTS
(UNAUDITED)
(4) EARNINGS PER SHARE RECONCILIATION
Net income (loss) per share of common stock is computed based upon the
weighted average number of shares outstanding during each period and including
the dilutive effect, if any, of stock options and warrants. SFAS 128 requires
the presentation of basic and diluted earnings (loss) per share for all periods
presented. As Ibis was in a net loss position for the three months ended March
31, 2000, common stock equivalents of 570,574 were excluded from the diluted
loss per share calculation as they would be antidilutive. As a result, diluted
loss per share is the same as basic loss per share for the three months ended
March 31, 2000.
The reconciliation of the numerators and denominators of the basic and
diluted net income (loss) per common share computations for Ibis' reported net
income (loss) is as follows:
<TABLE>
<CAPTION>
Three Months Ended
March 31,
-------------------------
1999 2000
----------- -----------
<S> <C> <C>
Basic net income (loss) ................. $ 246,081 $ (371,299)
=========== ===========
Weighted average common
shares outstanding-basic ............. 6,878,188 8,210,655
=========== ===========
Net additional common shares upon assumed
exercise of stock options and warrants 320,676 --
----------- -----------
Weighted average common
shares outstanding-diluted ........... 7,198,864 8,210,655
=========== ===========
Net income (loss) per common share
Basic .......................... $ 0.04 $ (0.05)
=========== ===========
Diluted ........................ $ 0.03 $ (0.05)
=========== ===========
</TABLE>
(5) INDUSTRY SEGMENTS
Ibis' reportable segments are SIMOX Wafer Products, SIMOX Equipment and
Other Products or Services. For purposes of segment reporting, equipment spares
and field service revenue are combined and reported as SIMOX Equipment.
Government contracts, other services and license revenue are combined and
reported as Other Products or Services. In previous financial statements spares
and field service revenue were included in the Other Products or Services
segment. This reclassification was made in the third quarter of 1999 and all
prior periods reflect this reclassification.
7
<PAGE>
IBIS TECHNOLOGY CORPORATION
NOTES TO FINANCIAL STATEMENTS
(UNAUDITED)
The table below provides information for the three months ended March
31, 1999 and 2000 pertaining to Ibis' three industry segments.
<TABLE>
<CAPTION>
SIMOX
WAFER SIMOX OTHER PRODUCTS
PRODUCTS EQUIPMENT OR SERVICES TOTAL
-------- --------- ----------- -----
<S> <C> <C> <C> <C>
NET REVENUES
Three Months Ended March 31, 1999 $ 1,299,485 $ 2,862,752 $ 285,626 $ 4,447,863
Three Months Ended March 31, 2000 1,643,760 315,944 79,408 2,039,112
OPERATING INCOME (LOSS)
Three Months Ended March 31, 1999 (13,770) 365,417 180,962 532,609
Three Months Ended March 31, 2000 314,997 (760,672) 27,164 (418,511)
ASSETS
December 31, 1999 5,145,320 10,912,431 645,291 16,703,042
March 31, 2000 9,095,055 11,539,359 18,953 20,653,367
CAPITAL EXPENDITURES
Three Months Ended March 31, 1999 165,548 -- -- 165,548
Three Months Ended March 31, 2000 2,836,915 29,645 -- 2,866,560
DEPRECIATION AND AMORTIZATION
OF PROPERTY AND EQUIPMENT
Three Months Ended March 31, 1999 291,663 11,965 -- 303,628
Three Months Ended March 31, 2000 249,231 10,946 860 261,037
</TABLE>
The table below provides the reconciliation of reportable segment
operating income (loss) and assets to Ibis' totals.
<TABLE>
<CAPTION>
THREE MONTHS ENDED MARCH 31,
----------------------------
SEGMENT RECONCILIATION 1999 2000
- ---------------------- ----- ----
<S> <C> <C>
Income (Loss) Before Income Taxes:
Total operating income (loss) for reportable segments $ 532,609 $ (418,511)
Corporate general & administrative expenses (434,448) (446,744)
Net other income 149,176 495,212
------------ -------------
Income (loss) before income taxes 247,337 (370,043)
============ =============
</TABLE>
8
<PAGE>
IBIS TECHNOLOGY CORPORATION
NOTES TO FINANCIAL STATEMENTS
(UNAUDITED)
<TABLE>
<CAPTION>
THREE MONTHS ENDED MARCH 31,
----------------------------
1999 2000
----- ----
<S> <C> <C>
Capital Expenditures:
Total capital expenditures for reportable segments 165,548 2,866,560
Corporate capital expenditures 104,226 56,704
------------ -------------
Total capital expenditures 269,774 2,923,264
============ ===========
Depreciation and Amortization:
Total depreciation and amortization for reportable segments 303,628 261,037
Corporate depreciation and amortization 30,390 46,425
------------ -----------
Total depreciation and amortization 334,018 307,462
=========== ==========
BALANCES AS OF
--------------
12/31/99 3/31/00
-------- -------
Assets:
Total assets for reportable segments 16,703,042 20,653,367
Cash & cash equivalents not allocated to segments 36,361,621 32,072,987
Other unallocated assets 662,841 550,913
------------ ------------
Total Assets 53,727,504 53,277,267
=========== ==========
</TABLE>
9
<PAGE>
IBIS TECHNOLOGY CORPORATION
PART I - ITEM 2
MANAGEMENT'S DISCUSSION AND ANALYSIS OF
FINANCIAL CONDITION AND RESULTS OF OPERATIONS
OVERVIEW
Ibis Technology Corporation ("Ibis") was formed in October 1987 and
commenced operations in January 1988. Ibis' initial activities consisted of
producing and selling SIMOX-SOI wafers and conducting research and development
activities. This research led to the development of a proprietary second
generation implanter, the Ibis 1000 which we began selling in 1996, and to other
proprietary process technology.
Initially, much of our revenue was derived from research and
development contracts and sales of wafers for military applications. Over the
years, there has been a shift in revenue to sales of SIMOX-SOI wafers for
commercial applications and sales of Ibis 1000 implanters. To date, most of our
customers that have purchased wafers for commercial applications have done so
solely for the purpose of characterizing and evaluating the wafers or for pilot
production. Thus, historical sales are not necessarily indicative of future
operations because such sales would not be considered of a recurring nature.
However, three of our customers have indicated their intentions to adopt
SIMOX-SOI technology in commercial products.
During 1999 and 2000, Ibis experienced quarterly fluctuations due to
the timing of receipt of equipment orders, use of the implanters for SIMOX-SOI
development, and dependence on a limited number of customers. We may continue to
experience fluctuations in revenue due to equipment sales, shifts in customer
demands during various stages of the SIMOX-SOI sales cycle and until we have a
sufficient number of Ibis 1000's on-line to support the various product lines,
wafer sizes and continued research and development efforts.
RESULTS OF OPERATIONS
FIRST QUARTER ENDED MARCH 31, 2000 COMPARED TO FIRST QUARTER ENDED MARCH 31,
1999
PRODUCT SALES. Wafer product sales increased $344,275, or 26%, to
$1,643,760 for the first quarter ended March 31, 2000 from $1,299,485 for the
first quarter ended March 31, 1999. The increase in product sales is
attributable to increased wafer sales by Ibis in Europe and Japan. Sales by Ibis
in the United States decreased overall during this three month period.
CONTRACT AND OTHER REVENUE. Contract and other revenue includes revenue
derived from government contracts, license agreements, characterization and
other services. Contract and other revenue decreased for the first quarter ended
March 31, 2000 to $79,408 from $285,626 for the first quarter ended March 31,
1999, a decrease of $206,218 or 72%. This decrease is attributable to a decrease
in revenues derived from government contracts and decreased license revenue.
10
<PAGE>
IBIS TECHNOLOGY CORPORATION
PART I - ITEM 2
MANAGEMENT'S DISCUSSION AND ANALYSIS OF
FINANCIAL CONDITION AND RESULTS OF OPERATIONS (CONTINUED)
EQUIPMENT REVENUE. Equipment revenue represents revenue recognized from
the sale of Ibis 1000 implanters, sales of spare parts and field service
revenue. Equipment revenue decreased to $315,944 for the first quarter ended
March 31, 2000 from $2,862,752 for the first quarter ended March 31, 1999, a
decrease of $2,546,808 or 89%. This decrease is attributable to a lack of Ibis
1000 implanter sales which was partially offset by an increase in field service
revenue and the sale of spare parts. Field service revenue accounted for $73,800
of equipment revenue for the first quarter ended March 31, 2000 as compared to
$39,624 of equipment revenue for the first quarter ended March 31, 1999. Sales
of spare parts accounted for $242,144 of equipment revenue for the first quarter
ended March 31, 2000 as compared to $33,128 of equipment revenue for the first
quarter ended March 31, 1999.
There was no equipment revenue in the first quarter of 2000, however,
due to changes in the sales process the company anticipates that it will record
future equipment sales based on shipment.
TOTAL SALES AND REVENUE. Total sales and revenue for the first quarter
ended March 31, 2000 was $2,039,112, a decrease of $2,408,751, or 54%, from
total revenue of $4,447,863 for the first quarter ended March 31, 1999. This
decrease resulted from the lack of Ibis 1000 implanter sales and the decrease in
contract and other revenue partially offset by increased product sales.
TOTAL COST OF SALES AND REVENUE. Cost of product sales for the first
quarter ended March 31, 2000 was $933,020, as compared to $1,246,083 for the
first quarter ended March 31, 1999, a decrease of $313,063 or 25%. Cost of
contract and other revenue for the first quarter ended March 31, 2000 was
$52,244, as compared to $104,665 for the first quarter ended March 31, 1999, a
decrease of $52,421, or 50%. Cost of equipment revenue for the first quarter
ended March 31, 2000 was $132,254 as compared to $1,970,966 for the first
quarter ended March 31, 1999, a decrease of $1,838,712 or 93%. The gross margin
for all sales was 45% for the first quarter ended March 31, 2000 as compared to
25% for the first quarter ended March 31, 1999. The increase in gross margin
percentage is attributable to the profit recognized from product sales for the
quarter. The fundamental fixed cost nature of product sales, which was absorbed
by a larger number of wafers sold during the first quarter of 2000 as compared
to the same quarter in the previous year, resulted in a positive impact on
margins. Cost of contract and other revenue consists of labor and materials
expended during the quarter. Contract margins can vary from year to year based
on the type of contracts that Ibis enters into. Additionally, different fee
arrangements and indirect cost absorption can contribute to margin variability.
GENERAL AND ADMINISTRATIVE EXPENSES. General and administrative
expenses for the first quarter ended March 31, 2000 were $446,744 (or 22% of
total revenue) as compared to $434,448 (or 10% of total revenue) for the first
quarter ended March 31, 1999, an increase of $12,296, or 3%. The increase is due
to increases in payroll and payroll related expenses incurred in the quarter.
11
<PAGE>
IBIS TECHNOLOGY CORPORATION
PART I - ITEM 2
MANAGEMENT'S DISCUSSION AND ANALYSIS OF
FINANCIAL CONDITION AND RESULTS OF OPERATIONS (CONTINUED)
MARKETING AND SELLING EXPENSES. Marketing and selling expenses for the
first quarter ended March 31, 2000 were $427,020 (or 21% of total revenue) as
compared to $207,170 (or 5% of total revenue) for the first quarter ended March
31, 1999, an increase of $219,850, or 106%. The increase in marketing and
selling expenses is primarily a result of an increase in the number of customer
support personnel, training, and public relations.
RESEARCH AND DEVELOPMENT EXPENSES. Internally funded research and
development expenses increased by $526,715 or 136%, to $913,085 (or 45% of total
revenue) for the first quarter ended March 31, 2000, as compared to $386,370 (or
9% of total revenue) for the first quarter ended March 31, 1999. The increase is
primarily due to an increase in personnel and consultants hired for Ibis' design
and development effort on our next generation oxygen implanter, the Ibis 2000.
INCOME (LOSS) FROM OPERATIONS. The loss from operations for the first
quarter ended March 31, 2000 was $865,255 as compared to income of $98,161 for
the first quarter ended March 31, 1999, a decrease of $963,416, or 982%. The
decrease in income from operations is the result of decreases in equipment
revenue and contract and other revenue, as well as the increase in operating
expenses, which were partially offset by increased product sales.
OTHER INCOME (EXPENSE). Total other income for the first quarter ended
March 31, 2000 was $495,212 as compared to $149,176 for the first quarter ended
March 31, 1999, an increase of $346,036, or 232%. The increase in total other
income is primarily attributable to increased interest income earned primarily
on the proceeds from the August 1999 public stock offering and reduced interest
expense on capitalized leases.
INCOME (LOSS) BEFORE INCOME TAXES. The loss before income taxes was
$370,043 for the first quarter ended March 31, 2000, as compared to a profit of
$247,337 for the first quarter ended March 31, 1999. The decrease of $617,380,
or 250%, is due to the decrease in equipment revenue and contract and other
revenue and increases in operating expenses, which were partially offset by
increased product sales and increased interest income.
IMPACT OF THE YEAR 2000 ISSUE
THE YEAR 2000 ISSUE
The Year 2000 Issue refers to potential problems with computer
systems or any equipment with computer chips or software that use dates where
the date has been stored as just two digits (e.g., 98 for 1998). On January 1,
2000, any clock or date recording mechanism incorporating date sensitive
software which was using only two digits to represent the year could have
recognized a date using 00 as the year 1900 rather than the year 2000. This
could have resulted in a system failure or miscalculations causing disruption of
operations, including, among other things, a temporary inability to process
transactions, send invoices, or engage in similar business activities.
12
<PAGE>
IBIS TECHNOLOGY CORPORATION
PART I - ITEM 2
MANAGEMENT'S DISCUSSION AND ANALYSIS OF
FINANCIAL CONDITION AND RESULTS OF OPERATIONS (CONTINUED)
COSTS ASSOCIATED WITH THE YEAR 2000 ISSUE
The costs incurred by Ibis to conduct the review of our internal
information systems and to identify the impact of the Year 2000 issue on our
major suppliers and customers were immaterial. The costs to implement our common
software system were not considered Year 2000 costs as they were included in our
software integration plan and were not accelerated due to Year 2000 issues. The
costs to perform upgrades to correct the Year 2000 Issues that we identified
were approximately $30,000.
The Year 2000 Issue did not have a material effect on Ibis' internal
information systems. We cannot be sure, however, that we will not in the future
identify non-compliant systems or other problems related to the Year 2000 issue
which may have a material adverse effect on our future operating results or
financial condition. In addition, we cannot be sure that the failure to ensure
Year 2000 capability by a supplier or another third party would not have a
material adverse effect on Ibis.
LIQUIDITY AND CAPITAL RESOURCES
As of March 31, 2000, Ibis had cash and cash equivalents of
$32,072,987, reflecting in large part our receipt of approximately $25 million
in net proceeds from the August, 1999 public sale of 1,000,000 shares of common
stock. During the first quarter ended March 31, 2000 Ibis consumed $1,636,321 in
cash from operating activities as compared to cash generated from operations in
the amount of $464,370 for the same period in 1999. Depreciation and
amortization expense for the first quarter ended March 31, 2000 and 1999 was
$307,462 and $334,018, respectively. This accounted for 15% and 8% of total
revenue, respectively. Due to the capital intensive nature of Ibis' business and
the anticipated expansion of its facilities and production capacity, management
expects that depreciation and amortization will continue to be a significant
portion of its expenses. To date, Ibis' working capital requirements have been
primarily funded through debt and equity financings. The principal use of cash
during the first quarter ended March 31, 2000 was to fund additions to property
and equipment which totaled $2,923,264. As of March 31, 2000, we had invested
$19,044,318 in property and equipment. At March 31, 2000, Ibis had commitments
to purchase $8,674,484 in material or subassemblies to be used for manufacturing
Ibis 1000 implanters currently under construction and approximately $1,904,198
in capital equipment purchases.
We anticipate that we may be required to raise substantial additional
capital in the future in order to finance further expansion of our manufacturing
capacity and our research and development programs. Our existing cash resources
together with funds generated from operations are believed to be sufficient to
support Ibis' operations on our anticipated scale for at least the next eighteen
months. Management of Ibis currently believes that this anticipated scale of
operations will include the addition of Ibis 1000 oxygen implanters (in addition
to our three oxygen implanters currently on-line), the purchase of support
equipment, the expansion of Ibis' facilities, and the design and development of
the next generation oxygen implanter, the Ibis 2000. Additional implanters are
expected to be transferred to production at various times as additional capacity
is needed to meet demand.
NEW ACCOUNTING PRONOUNCEMENTS
In June 1998, the Financial Accounting Standards Board issued SFAS 133,
"Accounting for Derivative Instruments and Hedging Activities" ("SFAS 133") that
establishes accounting and reporting requirements for derivative instruments and
for hedging activities. SFAS 133 requires companies to recognize all derivatives
as
13
<PAGE>
IBIS TECHNOLOGY CORPORATION
PART I - ITEM 2
MANAGEMENT'S DISCUSSION AND ANALYSIS OF
FINANCIAL CONDITION AND RESULTS OF OPERATIONS (CONTINUED)
either assets or liabilities in the statement of financial position at fair
value. If certain conditions are met, a derivative may be specifically
designated as a hedge of the exposures to changes in fair value of recognized
assets or liabilities or unrecognized firm commitments, a hedge of the exposure
to variable cash flows of a forecasted transaction, or a hedge of the foreign
currency exposure of a net investment in a foreign operation, unrecognized firm
commitments, an available-for-sale security or a foreign-currency denominated
forecasted transaction. The accounting for changes in fair value under SFAS 133
depends on the intended use of the derivative and the resulting designation. In
June 1999, the FASB decided that the effective date for adopting the
requirements of SFAS 133 should be delayed to fiscal years beginning after June
15, 2000. This delay, published as SFAS 137, applies to quarterly and annual
financial statements. Ibis is currently evaluating the effect SFAS 133 will have
on the results of its operations and its financial position.
In December 1999, the Securities and Exchange Commission issued Staff
Accounting Bulletin No. 101 ("SAB No. 101"), "Revenue Recognition in Financial
Statements". SAB No. 101 summarizes certain of the staff's views in applying
generally accepted accounting principles to revenue recognition in financial
statements. Management believes Ibis has complied with the provisions of SAB No.
101.
EFFECTS OF INFLATION
Ibis believes that over the past three years inflation has not had a
significant impact on our sales or operating results.
BUSINESS OUTLOOK
The Form 10-Q contains forward-looking statements within the meaning of
the "safe harbor" provisions of the Private Securities Litigation Reform Act of
1995 including statements regarding the continuation of fluctuations in revenue,
the expectation that depreciation and amortization will continue to be a
significant portion of expenses, the need for future additional capital and the
sufficiency of our current capital, and the anticipated scale of Ibis'
operations. Such statements are based on our current expectations and are
subject to a number of factors and uncertainties which could cause actual
results to differ materially from those described in the forward-looking
statements. Such factors and uncertainties include, but are not limited to, the
uncertainty that the performance advantages of SIMOX-SOI wafers will continue to
be realized commercially or that a commercial market for SIMOX-SOI wafers will
continue to develop; the dependence by Ibis on key customers (during 1997, 1998
and 1999, revenues from two customers averaged in the aggregate between 39% and
81% of our revenues, so that the loss of one or more of these major customers
and the failure of Ibis to obtain other sources of revenue could have a material
adverse impact on us); the loss of the services of one or more of our key
individuals, which could have a material adverse impact on Ibis; the dependence
by Ibis on key suppliers, so that the loss of services of one or more suppliers
could have a material adverse impact on us; the development of competing or
superior technologies and products from manufacturers, many of which have
substantially greater financial, technical and other resources than us; Ibis'
lack of experience in producing commercial quantities of our products at
acceptable costs; our ability to successfully complete the manufacture of our
implanters and that these implanters will be accepted by our customers; Ibis'
ability to develop and maintain strategic alliances for the manufacturing,
marketing and distribution of our products and sale of equipment; the cyclical
nature of the semiconductor industry, which has negatively affected our sales of
SIMOX-SOI wafers during industry downturns and which could continue to do so in
the future; the limited availability of critical materials and components for
wafer products and implanters, as a shortage of such materials and components or
a significant increase in the price thereof could have a material adverse effect
on our business and results of operations; the availability of additional
capital to fund expansion on acceptable terms, if at all; and general economic
conditions.
14
<PAGE>
IBIS TECHNOLOGY CORPORATION
PART I - ITEM 3
QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK
The exposure of market risk associated with risk-sensitive instruments
is not material to Ibis, as we do not transact our sales denominated in other
than United States dollars, invest primarily in short-term commercial paper,
hold our investments until maturity and have not entered into hedging
transactions.
15
<PAGE>
IBIS TECHNOLOGY CORPORATION
PART II
OTHER INFORMATION
Item 1 - LEGAL PROCEEDINGS
None
Item 2 - CHANGES IN SECURITIES
None
Item 3 - DEFAULTS UPON SENIOR SECURITIES
None
Item 4 - SUBMISSION OF MATTERS TO A VOTE OF SECURITY HOLDERS
None
Item 5 - OTHER INFORMATION
None
Item 6 - EXHIBITS AND REPORTS ON FORM 8-K
(a) Exhibits furnished as Exhibits hereto:
27 Financial Data Schedule
(b) Reports on Form 8-K:
The Company filed with the Securities and Exchange Commission
on February 22, 2000 a Current Report on Form 8-K for the
February 16, 2000 event announcing 1999 fourth quarter and
year end results.
16
<PAGE>
IBIS TECHNOLOGY CORPORATION
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned, thereunto duly authorized.
Ibis Technology Corporation
Date: May 11, 2000 By: /S/DEBRA L. NELSON
--------------------------------------------
Debra L. Nelson
Chief Financial Officer, Treasurer and Clerk
(principal financial and accounting officer)
Date: May 11, 2000 By: /S/THOMAS F. LACEY
--------------------------------------------
Thomas F. Lacey
Controller and Assistant Treasurer
17
<PAGE>
IBIS TECHNOLOGY CORPORATION
EXHIBIT INDEX
<TABLE>
<CAPTION>
EXHIBIT NO. DESCRIPTION PAGE
- ----------- ----------- ----
<S> <C> <C>
27 Financial Data Schedule 19
</TABLE>
18
<TABLE> <S> <C>
<PAGE>
<ARTICLE> 5
<MULTIPLIER> 1
<CURRENCY> U.S. DOLLARS
<S> <C>
<PERIOD-TYPE> 3-MOS
<FISCAL-YEAR-END> DEC-31-2000
<PERIOD-START> JAN-01-2000
<PERIOD-END> MAR-31-2000
<EXCHANGE-RATE> 1
<CASH> 32,072,987
<SECURITIES> 0
<RECEIVABLES> 3,527,996
<ALLOWANCES> 65,000
<INVENTORY> 7,851,226
<CURRENT-ASSETS> 45,304,860
<PP&E> 17,253,442
<DEPRECIATION> 9,658,546
<TOTAL-ASSETS> 53,277,267
<CURRENT-LIABILITIES> 4,711,120
<BONDS> 0
66,166
0
<COMMON> 0
<OTHER-SE> 48,538,630
<TOTAL-LIABILITY-AND-EQUITY> 53,277,267
<SALES> 1,959,704
<TOTAL-REVENUES> 2,039,112
<CGS> 1,065,274
<TOTAL-COSTS> 1,117,518
<OTHER-EXPENSES> 1,291,637
<LOSS-PROVISION> 0
<INTEREST-EXPENSE> 7,328
<INCOME-PRETAX> (370,043)
<INCOME-TAX> 1,256
<INCOME-CONTINUING> (371,299)
<DISCONTINUED> 0
<EXTRAORDINARY> 0
<CHANGES> 0
<NET-INCOME> (371,299)
<EPS-BASIC> (.05)
<EPS-DILUTED> (.05)
</TABLE>
